DreaminLMBC: Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC
Study Details
Study Description
Brief Summary
The purpose of this study is to further use DCE-MRI and ivim-dwi to predict the chemotherapy sensitivity of liver metastasis of breast cancer at an early stage, and to predict the treatment response of tumor at an early stage by using the changes of their functional parameters, and to compare the efficacy and advantages of IVIM functional parameters and DCE-MRI parameters in predicting the efficacy.To explore the efficacy of "perfusion" and "diffusion" parameters of magnetic resonance imaging as "biomarkers" for early prediction of chemotherapy response and prognosis of breast cancer patients with liver metastasis. And to provide guidance for optimizing the clinical treatment scheme of breast cancer patients with liver metastasis.
At the same time, this study will use the method of artificial intelligence to deeply mine the images, and further find out the indicators for early prediction of the therapeutic effect of liver metastasis of breast cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
The first MR examination was arranged within 7 days before treatment (baseline). The MRI scanning sequence included conventional T1, T2 weighted imaging, T1+dynamic contrast enhanced imaging, and IVIM-DWI imaging.The second and third MR examinations were arranged within 7 days after the first chemotherapy and the second chemotherapy. The examination steps and parameters were the same as those of the first examination.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with liver metastasis from breast cancer requiring antitumor therapy Patients with liver metastasis from breast cancer requiring antitumor therapy |
Drug: Chemotherapy
All patients were given 2 cycles of chemotherapy, including the chemotherapy recommended by the clinical treatment guidelines for advanced metastatic breast cancer, which can be combined with targeted or immune or endocrine therapy.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Correlation between DCE-MRI parameters combined with IVIM parameters and short-term efficacy of chemotherapy in patients with liver metastasis of breast cancer [September 2025]
Correlation between DCE-MRI parameters (Ktrans, Ve, Kep) combined with IVIM parameters (D*, D, f) and short-term efficacy of chemotherapy in patients with liver metastasis of breast cancer
- Correlation between DCE-MRI parameters combined with IVIM parameters and long-term efficacy of chemotherapy in patients with liver metastasis of breast cancer [September 2025]
Correlation between DCE-MRI parameters (Ktrans, Ve, Kep) combined with IVIM parameters (D*, D, f) and long-term efficacy of chemotherapy in patients with liver metastasis of breast cancer
Secondary Outcome Measures
- The consistency of DCE-MRI parameters and IVIM parameters between different observers and the same observer. [September 2025]
The consistency of DCE-MRI parameters and IVIM parameters between different observers and the same observer.
- Using artificial intelligence method to deeply mine images, find out new indicators to predict the curative effect of liver metastasis treatment of breast cancer in early stage. [September 2025]
Using artificial intelligence method to deeply mine images, find out new indicators to predict the curative effect of liver metastasis treatment of breast cancer in early stage.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The primary lesion was pathologically confirmed to be breast cancer, and the patients diagnosed by two imaging methods or pathologically confirmed to be liver metastasis of breast cancer had at least one liver metastasis with the longest diameter ≥ 10mm;
-
No second primary malignant tumor;
-
ECOG score, 0-2 ;
-
The organ function is normal and can tolerate chemotherapy and other anti-tumor treatments;
-
The patient plans to receive systemic chemotherapy or systemic anti-tumor treatment, and the whole process of cooperative treatment. The patient has good compliance with the planned treatment and follow-up, can understand the research process of this study and sign a written informed consent；
-
Contraception during the study period and within 6 months after treatment, non lactation period.
Exclusion Criteria:
-
For patients contraindicated to MR examination, such as built-in metal instruments and allergy to contrast agents;
-
The patient had diffuse liver metastasis or the number of liver metastatic tumors was more than 5;
-
Patients who cannot complete 2 cycles of chemotherapy or systemic anti-tumor treatment;
-
Unable to cooperate with follow-up；
-
Patients who are not suitable for the study according to the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Zhejiang Cancer Hospital | Hangzhou | Zhejiang | China | 310022 |
Sponsors and Collaborators
- Zhejiang Cancer Hospital
Investigators
- Principal Investigator: Ping Huang, Zhejiang Cancer Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ZCHBC022